Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CO2MO
2025-520913-29-00Phase 4Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pembrolizumab, nivolumab and ipilimumab in cutaneous melanoma (CM), sponsored by Leiden University Medical Center. Primary endpoint: 1-year progression-free survival. Planned start Jul 2025; status: authorised.
02
Drugs
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2025-520913-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520913-29-00.